GOSS
$0.47
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.
Recent News
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -7.14% and +81.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Gossamer Bio: Q4 Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 21 cents. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 20 cents per share.
Gossamer Bio options imply 46.1% move in share price post-earnings
Pre-earnings options volume in Gossamer Bio (GOSS) is normal with puts leading calls 19:3. Implied volatility suggests the market is anticipating a move near 46.1%, or 0c, after results are released. Median move over the past eight quarters is 3.5%.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFly – the u
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street Valuations
The average fair value estimate on Gossamer Bio has reset from about US$9.50 to roughly US$3.69, signaling a steep reassessment of what analysts think the shares may be worth. That shift lines up with Street research that now clusters price targets between US$0.30 and US$5, as views split between enthusiasm around seralutinib and concerns about regulation and the balance sheet. Read on to see how this evolving narrative is taking shape and what you might want to watch next. Stay updated as...